EUDA Health Holdings Limited announced that Shenzhen Inno Immune Co., Ltd. has received approval from the Shenzhen Key Industry R&D Program for its TCR‑T cell therapy development. The approval, granted on April 28 2026, authorises the program to run from January 1 2026 to December 31 2028 and may bring up to US$434,688 in government funding to support the project.
Under a non‑exclusive distribution arrangement, EUDA holds the rights to market and sell the approved immunotherapies in Malaysia through its subsidiary CK Health Plus Sdn Bhd. Treatments will be manufactured and administered in China, while EUDA will be the sole distributor in the Malaysian market, creating a new revenue stream for the Singapore‑based company. CK Health Plus was acquired in May 2024 for US$15 million and already operates as a direct seller of wellness products in Malaysia.
The approval expands EUDA’s portfolio beyond its existing non‑invasive wellness services and positions the company to tap into the growing cellular‑therapy market in Southeast Asia. However, the company is currently facing significant financial challenges. Recent filings show net losses for 2024 and 2025, a working‑capital deficit, and low cash reserves. An auditor’s report raised substantial doubt about EUDA’s ability to continue as a going concern, and the company has received a Nasdaq notice for failing to maintain the minimum market value of listed securities, with a compliance deadline of October 20 2026 to avoid delisting.
Management stated that the approval aligns with EUDA’s strategy to expand access to advanced, science‑driven therapies and supports its broader focus on preventive and longevity‑focused healthcare across Asia. The company views the partnership with Shenzhen Inno as a key step toward building a biotechnology platform that complements its digital health ecosystem.
Market reaction to the approval was initially positive, with investors noting the potential for a new revenue stream. In the longer term, the company’s financial distress and Nasdaq compliance risk have tempered enthusiasm, as the market weighs the regulatory win against the backdrop of ongoing losses and liquidity concerns.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.